Phibro Animal Health Corporation's Zoetis MFA acquisition has revitalized its overall growth. Animal Health is now around 75% of their total sales, and its integration should be finalized by Q4 2025.
Zoetis is a global leader in animal health with strong organic growth, robust product innovation, and strategic M&A driving long-term revenue and earnings expansion. The company boasts exceptional div
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for

Zoetis: Why I Decided To Invest In The Stock

01:45am, Monday, 25'th Aug 2025
Zoetis remains the global leader in animal health, with 68% of revenue from companion animals. Q2 results showed 8% organic sales growth and 15% adjusted earnings growth. Librela sales in the U.S. dec
Right now is not a good time in the healthcare sector. Various companies across the space are well below highs while the broader stock market chugs along at all-time highs.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate princ
Ah, 10 years ago. It was 2015, and selfie sticks and hoverboards were all over.
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those
It can be tempting to try to predict market movements so you buy low and sell high, but it's notoriously difficult to execute successfully. Even if you succeed once or twice, replicating that often en
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
Zoetis Inc. (NYSE:ZTS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Kristin C. Peck - CEO & Director Steven Frank - Vice President of Investor Relations Wetteny N.
Animal health firm Zoetis Inc.  ZTS on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates a
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE